Peripheral neuropathy in the COVID-19 era

The term peripheral neuropathy refers to disorders of the nervous system (PNS) including single and multiple (asymmetric) mononeuropathies, symmetrical involvement many nerves (polyneuropathy). Further classification depends on a mixture phenomenological, neurophysiological, pathological aetiological parameters. temporal evolution symptoms divides polyneuropathy (PN) into acute or chronic. Acute PN e.g. Guillain-Barré syndrome (GBS) is rare but an important entity recognise because whilst at times severe, it treatable. Most are chronic usually develop over several months. Coronavirus disease 2019 (COVID-19) contagious caused by SARS-CoV-2. Symptoms COVID-19 variable, often include fever, cough, headache, fatigue, breathing difficulties, loss smell taste. Neurological complications have been reported in context infection both subacute phase, as part post-COVID result vaccination against In has that GBS prevalence 15 cases per 100,000 SARS-CoV-2 infections. Demyelinating GBSs variant particular most prevalent. Although not necessarily directly SARS-CoV-2, prolonged stay ICUs associated with increased risk ICU related neuro-myopathy. preliminary results ongoing prospective observational studies suggest patients suffered from developing mild axonal shows evidence length dependency. Interestingly, – even absence electrophysiologically confirmed 1 5 deterioration pre-existing neuropathic development new symptoms, particularly pain, after COVID-19. Such tend persist for needed describe natural history PNS during infection.